Jeena Sikho Lifecare Limited has informed the stock exchanges, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, about the publication of nine research works in the Journal of Applied Science and Education (JASE). The publications comprise seven case studies and two case reports, authored by medical professionals associated with the company, including its Managing Director, senior consultants, and Ayurvedic experts. The disclosure was made on 04 May, 2026.

Research Publications Overview

The nine publications collectively cover Ayurvedic clinical approaches to a range of medical conditions, reflecting the company's focus on evidence-based Ayurvedic practice. The authors include professionals directly associated with Jeena Sikho Lifecare Limited. The full details of all published works are presented below.

Scope of Clinical Research

The published works span several significant medical conditions addressed through Ayurvedic frameworks. The research areas covered across the nine publications include:

• Chronic Kidney Disease (CKD): Multiple publications addressing CKD at various stages, including End-Stage Renal Disease (Stage V), acute kidney disease, and CKD in combination with Type 2 Diabetes and Hypertension
• Musculoskeletal Conditions: Ayurvedic management of Gridhrasi (Sciatica) and Sandhigata Vata (Osteoarthritis)
• Paediatric Case: Ayurvedic treatment of kidney-related disorder (Vrikka Vikar) in a child
• Liver Condition: Management of liver cirrhosis (Yakritdalyodara) using Shamana Chikitsa and Panchakarma therapies
• Integrated Perspectives: Classical Ayurvedic disease pathology (Samprapti) and treatment (Chikitsa) for CKD with associated metabolic conditions

Regulatory Disclosure

The intimation was submitted to both the National Stock Exchange of India Limited and BSE Limited in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015. The disclosure was signed by Manish Grover, Managing Director (DIN: 07557886), from Zirakpur, Punjab, on 04 May, 2026. The company has also made the information available on its official website at www.jeenasikho.com . Links to all nine published articles have been provided to the exchanges for their records.

Jeena Sikho Lifecare Limited has officially notified stock exchanges that it does not qualify as a Large Corporate under SEBI's regulatory framework for the financial year 2026. The company submitted this disclosure to both the National Stock Exchange of India Limited and BSE Limited on April 16, 2026, ensuring compliance with regulatory requirements.

Regulatory Compliance Framework

The notification was made pursuant to several SEBI circulars, including SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, and circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023. These circulars pertain to fund raising by issuance of debt securities by large entities and establish specific criteria for Large Corporate classification.

Financial Position and Classification Details

The company provided detailed financial information to support its non-Large Corporate status:

The company confirmed that its outstanding borrowing of ₹0.43 crore as of March 31, 2026, falls significantly below the threshold criteria established under the SEBI circulars for Large Corporate identification.

Corporate Structure and Operations

Jeena Sikho Lifecare Limited operates over 120 Ayurveda clinics and hospitals, positioning itself in the healthcare sector with a focus on traditional medicine. The company maintains its registered office at SCO-11, Kalgidhar Enclave, Baltana, Zirakpur, Punjab-140604, while its corporate office is located at B-26, Opp. Metro Pillar No. 223, Rohtak Road, New Multan Nagar, Delhi - 110056.

Management Authorization

The disclosure was authorized by Manish Grover, Managing Director (DIN: 07557886), and signed digitally on April 16, 2026. The submission included signatures from key executives including Smita Chaturvedi, Company Secretary and Compliance Officer, and Nanak Chand, Chief Financial Officer, demonstrating proper corporate governance protocols.

Regulatory Implications

By confirming its non-Large Corporate status, Jeena Sikho Lifecare Limited clarifies that it is not subject to the enhanced regulatory requirements and borrowing frameworks applicable to larger entities. This classification affects the company's debt issuance procedures and compliance obligations under SEBI regulations, providing clarity to investors and regulatory authorities regarding its operational framework for the financial year 2026.